Macquarie Group’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-17,092
| Closed | -$174K | – | 1729 |
|
|
2025
Q1 | $174K | Hold |
17,092
| – | – | ﹤0.01% | 1539 |
|
|
2024
Q4 | $238K | Hold |
17,092
| – | – | ﹤0.01% | 1500 |
|
|
2024
Q3 | $333K | Hold |
17,092
| – | – | ﹤0.01% | 1518 |
|
|
2024
Q2 | $318K | Hold |
17,092
| – | – | ﹤0.01% | 1520 |
|
|
2024
Q1 | $240K | Hold |
17,092
| – | – | ﹤0.01% | 1510 |
|
|
2023
Q4 | $145K | Hold |
17,092
| – | – | ﹤0.01% | 1567 |
|
|
2023
Q3 | $153K | Hold |
17,092
| – | – | ﹤0.01% | 1554 |
|
|
2023
Q2 | $147K | Hold |
17,092
| – | – | ﹤0.01% | 1568 |
|
|
2023
Q1 | $180K | Hold |
17,092
| – | – | ﹤0.01% | 1563 |
|
|
2022
Q4 | $579K | Sell |
17,092
-171
| -1% | -$8.28K | ﹤0.01% | 1494 |
|
|
2022
Q3 | $841K | Sell |
17,263
-260
| -1% | -$15.5K | ﹤0.01% | 1459 |
|
|
2022
Q2 | $999K | Hold |
17,523
| – | – | ﹤0.01% | 1481 |
|
|
2022
Q1 | $1.42K | Sell |
17,523
-140
| -0.8% | -$20.7K | ﹤0.01% | 1463 |
|
|
2021
Q4 | $3.58M | Hold |
17,663
| – | – | ﹤0.01% | 1211 |
|
|
2021
Q3 | $4.76M | Sell |
17,663
-177
| -1% | -$42.6K | ﹤0.01% | 1120 |
|
|
2021
Q2 | $4.59M | Buy |
17,840
+243
| +1% | +$67.3K | ﹤0.01% | 1154 |
|
|
2021
Q1 | $5.28M | Sell |
17,597
-123
| -0.7% | -$38.3K | 0.01% | 894 |
|
|
2020
Q4 | $4.52M | Hold |
17,720
| – | – | 0.01% | 903 |
|
|
2020
Q3 | $4.41M | Buy |
17,720
+47
| +0.3% | +$14.8K | 0.01% | 863 |
|
|
2020
Q2 | $6.14M | Buy |
17,673
+74
| +0.4% | +$23.1K | 0.01% | 752 |
|
|
2020
Q1 | $4.71M | Buy |
17,599
+6,092
| +53% | +$1.88M | 0.01% | 730 |
|
|
2019
Q4 | $3.73M | Buy |
11,507
+147
| +1% | +$42.6K | 0.01% | 882 |
|
|
2019
Q3 | $3.1M | Hold |
11,360
| – | – | 0.01% | 894 |
|
|
2019
Q2 | $6.06M | Buy |
11,360
+287
| +3% | +$144K | 0.01% | 722 |
|
|
2019
Q1 | $5.58M | Hold |
11,073
| – | – | 0.01% | 747 |
|
|
2018
Q4 | $5.46M | Sell |
11,073
-60
| -0.5% | -$36.2K | 0.01% | 724 |
|
|
2018
Q3 | $10.2M | Buy |
11,133
+133
| +1% | +$114K | 0.02% | 640 |
|
|
2018
Q2 | $8.06M | Buy |
11,000
+9,968
| +966% | +$11.5M | 0.01% | 679 |
|
|
2018
Q1 | $1.65M | Sell |
1,032
-1,164
| -53% | -$1.5M | ﹤0.01% | 1046 |
|
|
2017
Q4 | $1.97M | Buy |
+2,196
| New | +$1.3M | ﹤0.01% | 1034 |
|
|
2013
Q3 | – | Sell |
-10,395
| Closed | -$1.8M | – | 1635 |
|
|
2013
Q2 | $1.8M | Buy |
+10,395
| New | +$1.59M | ﹤0.01% | 952 |
|
Other funds holding NKTR
NCM
TCM
Macquarie Group's NKTR Position: Q2 2025 in Review
Macquarie Group sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 17,092 shares — an estimated $174K sold.
Macquarie Group first reported a position in NKTR in Q2 2013 and held it in 31 quarters. The position peaked at $10.2M in Q3 2018. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.
- Macquarie Group reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
- Macquarie Group sold 17,092 Nektar Therapeutics shares in Q2 2025, an estimated $174K.
- Macquarie Group first reported a position in Nektar Therapeutics in Q2 2013 and held it in 31 quarters.
- Macquarie Group's Nektar Therapeutics position peaked at $10.2M in Q3 2018.
- 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.
Based on Macquarie Group's 13F filing for Q2 2025, filed 14 Aug 2025.